AJCN Tufts Nutrition Symposium, Boston Sept 24-26
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Desai, T. K.
Right arrow Articles by Cejka, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Desai, T. K.
Right arrow Articles by Cejka, J.
Agricola
Right arrow Articles by Desai, T. K.
Right arrow Articles by Cejka, J.

American Journal of Clinical Nutrition, Vol 55, 708-711, Copyright © 1992 by The American Society for Clinical Nutrition, Inc


ORIGINAL RESEARCH COMMUNICATIONS

Taurine deficiency after intensive chemotherapy and/or radiation

TK Desai, J Maliakkal, JL Kinzie, MN Ehrinpreis, GD Luk and J Cejka
Department of Medicine, Harper Hospital, Wayne State University, Detroit, MI 48201.

Taurine, a nonessential amino acid (AA), is the most abundant free AA in the intracellular space. We measured plasma AA concentrations in 36 patients 7-28 d after intensive chemotherapy and/or radiation. Plasma taurine concentrations were uniformly low in all patients (20.0 +/- 6.4 mumol/L, mean +/- SD). Plasma taurine in 11 healthy volunteer control subjects was 45.0 +/- 20.3 mumol/L (P less than 0.001). Other AA concentrations, specifically those of precursor AAs methionine and cystine, were normal. We prospectively measured plasma AA concentrations in 12 patients before starting and 6-10 d after completing intensive cytotoxic treatment. Values before treatment were 37.2 +/- 11.6, 109.6 +/- 30.7, and 18.5 +/- 4.8 for taurine, cystine, and methionine, respectively, and were 24.3 +/- 6.0, 111.2 +/- 23.8, and 24.0 +/- 14.5 after treatment. Pretreatment plasma taurine correlated directly with the magnitude of decrease in plasma taurine during cytotoxic treatment (n = 12, r = 0.85, P less than 0.01). Intensive cytotoxic chemotherapy and/or radiation leads to a reduction in plasma taurine concentrations without any change in its precursor AAs, methionine and cystine. The clinical relevance of plasma taurine depletion will need further study.


This article has been cited by other articles:


Home page
Integr Cancer TherHome page
J. M. Wallace
Integrative Tumor Board: Glioblastoma Multiforme: Nutritional and Botanical Approach
Integr Cancer Ther, June 1, 2004; 3(2): 152 - 163.
[PDF]


Home page
J. Nutr.Home page
P. Furst and P. Stehle
What Are the Essential Elements Needed for the Determination of Amino Acid Requirements in Humans?
J. Nutr., June 1, 2004; 134(6): 1558S - 1565S.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
P. Fürst
Old and New Substrates in Clinical Nutrition
J. Nutr., May 1, 1998; 128(5): 789 - 796.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by The American Society for Nutrition